海外の治験の状況「1」での検索結果
1037件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Not recruiting
- A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen
- HIV Infections;HIV Infections;HIV Infections;HIV Infections
- Argentina, Australia, Chile, China, France, Germany, Hong Kong, India, Ireland, Malaysia, Mexico, New Zealand, Nigeria, Peru, Singapore, South Africa, Taiwan, United Kingdom, Vietnam
- 2009-07-01
Not Recruiting
- A 52-WEEK MULTICENTER, OPEN-LABEL, RANDOMIZED, PARALLEL, TWO - ARM STUDY COMPARING EXUBERA® (INHALED HUMAN INSULIN) VS. HUMALOG® (INSULIN LISPRO), BOTH IN COMBINATION WITH INSULIN GLARGINE IN SUBJECTS WITH TYPE 1 DIABETES MELLITUS.
- Type 1 Diabetes MedDRA version: 8.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus
- Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Netherlands, Portugal, Sweden, United Kingdom
- 2006-10-26
Not recruiting
- Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
- Renal Cell Carcinoma;Renal Cell Carcinoma;Renal Cell Carcinoma;Renal Cell Carcinoma
- Argentina, Australia, Austria, Canada, Chile, China, Denmark, Finland, France, Germany, Hong Kong, Hungary, Italy, Korea, Republic of, Netherlands, Singapore, Spain, Sweden, Switzerland, United Kingdom, United States
- 2007-05-15
Not Recruiting
- Comparative Effects of Telmisartan and Candesartan on glucose metabolism in patients with chronic heart failure - Sartans and glucosemetabolism
- both investigated drugs are well established in the treatment of heart failure or hypertension respectively. As the investigateed Patients have this conditions according to the inclusion criteria, treatment will be given as clinical appropriate. Background thearpy will be given according the guidelines of the ESC over the study period.
- Austria
- 2005-10-27
Not Recruiting
- Efficacy and safety of adding LX4211 (an investigational oral compound) for patients with Type 1 Diabetes Mellitus (T1D) who have inadequate control of their blood glucose (sugar) levels on insulin alone.
- Type 1 Diabetes Mellitus br>MedDRA version: 17.1 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Austria, Belgium, Bulgaria, France, Germany, Hungary, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Slovakia, Spain, Sweden, Switzerland, United Kingdom
- 2015-03-05
Not recruiting
- Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
- Type 1 Diabetes Mellitus;Type 1 Diabetes Mellitus;Type 1 Diabetes Mellitus
- Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Mexico, Romania, Spain, Sweden, United Kingdom, United States
- 2014-10-15
Not Recruiting
- A PHASE III CLINICAL TRIAL TO STUDY THE SAFETY AND EFFICACY OF MK-1293 COMPARED TO LANTUS™ IN SUBJECTS WITH TYPE 1 DIABETES MELLITUS
- -E10 Insulin-dependent diabetes mellitus br>Insulin-dependent diabetes mellitus;Insulin-dependent diabetes mellitus
- Australia, Colombia, Mexico, New Zealand, South Africa, Spain, United States
- 2014-02-27
Not Recruiting
- Standardized Evaluation of SPIDIMAn Glucose Monitoring System under routine environmental conditions
- Diabetes mellitus type 1;E10 - Insulin-dependent diabetes mellitus
- Austria
- 2015-12-17
Not Recruiting
- Standardized Procedure for the Assessment of new-to-market Continuous glucosE monitoring systems
- Diabetes Mellitus Type 1 Nutritional, Metabolic, Endocrine Insulin-dependent diabetes mellitus
- Austria, France, Germany, Italy, Netherlands
- 2012-08-02
Not Recruiting
- Collection of and monitoring continuous glucose data to test algorithms for a glucose monitor (DATA Trial)
- Diabetes mellitus type 1 Nutritional, Metabolic, Endocrine Insulin-dependent diabetes mellitus
- Austria, Germany, Italy, Netherlands
- 2011-10-25